Anika Therapeutics | ANIK - Operating Expenses


Anika Therapeutics reported $137.28M in Operating Expenses for its fiscal quarter ending in June of 2026.





Operating Expenses Change Date
Abbott USD 11.66B 1.2B Sep/2026
Agenus USD -199.08M 22.15M Jun/2026
Agios Pharmaceuticals USD 155.3M 24.53M Jun/2026
Anika Therapeutics USD 137.28M 3.38M Jun/2026
Arrowhead Research USD 245.35M 30.35M Jun/2026
Enanta Pharmaceuticals USD 126.59M 346.51M Dec/2025
Halozyme Therapeutics USD 198M 4.66M Sep/2026
Heron Therapeutics USD 40.55M 1.46M Dec/2025
Insmed USD 606.26M 79.46M Sep/2026
Integra LifeSciences USD 368.53M 674.84M Sep/2026
Intrexon USD 61.56M 26.1M Jun/2024
J&J USD 18.93B 1.09B Sep/2026
Karyopharm Therapeutics USD 61.83M 9.9M Mar/2026
Ligand Pharmaceuticals USD 94.5M 39.4M Sep/2026
MacroGenics USD 42.87M 21.68M Jun/2026
Merit Medical Systems USD 358.44M 20.72M Jun/2026
Rigel Pharmaceuticals USD 117.61M 35.67M Sep/2025
Sangamo BioSciences USD 33.87M 12.89M Jun/2024
Sanofi EUR 10.51B 598M Sep/2026
Smith & Nephew USD 2.59B 71M Jun/2026
Stryker USD 4.8B 118M Jun/2026
Veracyte USD 133.73M 7.37M Sep/2026
Xencor USD 87.82M 5.44M Jun/2026
Zimmer Biomet Holdings USD 1.72B 110.9M Sep/2026